

Quarterly Results and Investor Conference Call Notification

17 January, 2019 – Minnesota, United States – Osprey Medical (ASX:OSP) today advises it will release its Appendix 4C Quarterly Cash Flow Report for the period ending 31st December 2018, on Tuesday 29th January 2019.

Investors are invited to join a conference call hosted by CEO Mike McCormick on Tuesday 29th January 2019 at 9:00am Australian Eastern Daylight Time (6:00am Hong Kong/Singapore, 4:00pm Monday 28th January 2019 US Minneapolis, MN).

To pre-register, please follow this link:

<https://services.choruscall.com.au/diamondpass/ospreymedical-224103-invite.html>

You will receive a calendar notification with dial-in details and a PIN for fast track access to the call.

Contact details:

Media

Kyahn Williamson

WE Buchan

M: (61) 401 018 828

kwilliamson@we-buchan.com

Investors

Thomas Duthy

Nemean Group

M: (61) 402 493 727

tduthy@ospreymed.com

Company

Doug Schoenberg

VP of Marketing

T: (952) 955 8230

dschoenberg@ospreymed.com

About Osprey Medical (ASX:OSP)

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast Induced Acute Kidney Injury (AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ Plus System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

Foreign Ownership Restriction

Osprey's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.